Description
Release form
film-coated tablets.
Packing
30 pcs.
Contraindications
Hypersensitivity to losartan, sulfonamide derivatives and other components of
Anuria
Severe renal impairment (creatinine clearance (CC) less than 30 ml / min. )
Hyperkalemia
Dehydration (including when taking high doses of diuretics)
Severe hepatic impairment
Refractory hypokalemia
Pregnancy and lactation
Arterial hypotension
Deficiency or lactosis sardlacta glucose / galactose malabsorption syndrome.
Use during pregnancy and lactation
There are no data on the use of losartan during pregnancy. Renal perfusion of the fetus, which depends on the development of the renin-angiotensin system, begins to function in the third trimester of pregnancy. The risk to the fetus increases with losartan in the second and third trimesters. When pregnancy is established, Lorista ND therapy should be stopped immediately. If necessary, the appointment of the drug during lactation, it is necessary to stop breastfeeding.
Special instructions
May be prescribed with other antihypertensives.
There is no need for special selection of the initial dose for elderly patients.
The drug can increase the concentration of urea and creatinine in blood plasma in patients with bilateral renal artery stenosis or single kidney renal artery stenosis.
Hydrochlorothiazide can enhance arterial hypotension and disturbances in the water-electrolyte balance (decrease in circulating blood volume, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypokalemia), impair glucose tolerance, reduce calcium excretion in urine and cause a transient, slight increase in blood plasma concentration, a slight increase in blood concentration increase the concentration of cholesterol and triglycerides, provoke the occurrence of hyperuricemia and / or gout.
Taking medications directly acting on the renin-angiotensin system during the second and third trimesters of pregnancy can lead to fetal death. If pregnancy occurs, drug withdrawal is indicated. The use of diuretics is usually not recommended for pregnant women due to the risk of jaundice in the fetus and newborn, and maternal thrombocytopenia. Diuretic therapy does not prevent the development of toxicosis of pregnancy.
Composition
1 tablet contains:
Active ingredients:
losartan potassium 100 mg
hydrochlorothiazide 12.5 mg.
Excipients:
Pregelatinized starch
MCC
Lactose monohydrate
Magnesium stearate
Sheath:
Hypromellose
Macrogol 4000
Dye quinolitol (yellow) tinolitol 1 d1 tinolite
Dosage and administration
Inside, regardless of food intake.
Lorista N can be combined with other antihypertensive agents.
Arterial hypertension. The initial and maintenance dose is 1 tablet. Lorista N (50 / 12.5 mg) 1 time per day. The maximum antihypertensive effect is achieved within 3 weeks of therapy. To achieve a more pronounced effect, it is possible to increase the dose of the drug to 2 tablets. Lorista N (50 / 12.5 mg) 1 time per day. The maximum daily dose is 2 tablets. drug Lorista N.
In patients with reduced BCC (for example, while taking large doses of diuretics), the recommended initial dose of losartan in patients with hypovolemia is 25 mg once a day. In this regard, the therapy of Lorista N must be started after the abolition of diuretics and correction of hypovolemia.
In elderly patients and patients with moderate renal failure, including those on dialysis, no initial dose adjustment is required.
Reducing the risk of cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. The standard initial dose of losartan is 50 mg once a day.
Side effects of
On the part of the blood and lymphatic system: infrequently – anemia, Shenlein-Genoch disease.
On the part of the immune system: rarely – anaphylactic reactions, angioedema (including swelling of the larynx and tongue, causing obstruction of the airways and / or swelling of the face, lips, pharynx).
From the side of the central nervous system and peripheral nervous system: often – headache, systemic and non-systemic dizziness, insomnia, fatigue infrequently – migraine.
From the cardiovascular system: often – orthostatic hypotension (dose-dependent), palpitations, tachycardia rarely – vasculitis.
From the respiratory system: often – cough, upper respiratory tract infections, pharyngitis, swelling of the nasal mucosa.
From the gastrointestinal tract: often – diarrhea, dyspepsia, nausea, vomiting, abdominal pain.
From the hepatobiliary system: rarely – hepatitis, impaired liver function.
From the skin and subcutaneous fat: infrequently – urticaria, pruritus.
From the side of the musculoskeletal system and connective tissue: often – myalgia, back pain infrequently – arthralgia.
Other: often – asthenia, weakness, peripheral edema, chest pain.
Laboratory indicators: often – hyperkalemia, an increase in the concentration of hemoglobin and hematocrit (not clinically significant) sometimes – a moderate increase in the level of urea and creatinine in the blood serum is very rare – an increase in the activity of liver and bilirubin enzymes.
Overdose
Losartan
Symptoms: severe BP, tachycardia bradycardia caused by parasympathetic (vaginal) stimulation.
Treatment: forced diuresis, symptomatic therapy, hemodialysis is ineffective.
Hydrochlorothiazide
Symptoms: The most common symptoms are due to electrolyte deficiency (hypokalemia, hypochloremia, hyponatremia) and dehydration due to excessive diuresis. With concomitant administration of cardiac glycosides, hypokalemia may aggravate the course of arrhythmias.
Treatment: symptomatic.
Storage conditions
Store in a dry place, at a temperature not exceeding 30 ° C.
Active ingredient
hydrochlorothiazide, Losartan
orma
tablet
KRKA d.d. Novo mesto AO, Slovenia
